Trial Profile
Compassionate use of Bosutinib in patients with chronic myeloid leukemia who are resistant or intolerant to Imatinib, Dasatinib and Nilotinib
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 19 Dec 2015 New trial record
- 08 Dec 2015 Results (n = 59) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology